Aerosolised levofloxacin in cystic fibrosis

Expert Opinion on Orphan Drugs

Volumn 1, Issue 7, 2013, Pages 549-556

  Döring, Gerd ^a   Dalhoff, Axel ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antibiotics; Ciprofloxacin; Cystic fibrosis; Fluoroquinolones; Levofloxacin

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZTREONAM; CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LEVOFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; GENE THERAPY; HEREDITY; HUMAN; LUNG DISEASE; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SPUTUM; TISSUE DISTRIBUTION;

EID: 84896699562     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.820133     Document Type: Review

References (69)

1. Hodson M, Geedes D, Bush A. Cystic fibrosis. Arnold, London; 2007
2. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67
3. Doring G, Hoiby N; for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67
4. Doring G, Flume P, Heijerman H, Elborn JS; for the Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461
5. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7:450
6. Cystic Fibrosis Foundation. Patient registry annual report 2011. Bethesda; Maryland, USA: 2006
7. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-65
8. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73
9. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80 . First description of CFTR.
10. Cystic Fibrosis Genetic Analysis Consortium. Available from: http:/www. genet.sickkids.on.ca/cftr/
11. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681
12. Doring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 2009;11:208
13. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25
14. Rogers GB, Hoffman LR, Doring G. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J Cyst Fibros 2011;10:387
15. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001
16. Doring G, Knight R, Bellon G. Immunology of cystic fibrosis. In: Hodson ME, Geddes D, editors. Cystic fibrosis. Arnold; London: 2000. p. 109
17. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187
18. Cystic Fibrosis Foundation. Patient registry annual report 2011. Bethesda; Maryland, USA: 2012
19. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551d mutation. N Engl J Med 2011;365:1663-72
20. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010;5:1663-74
21. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288:1251-4
22. Levy J. Antibiotic activity in sputum. J Pediatr 1986;108:841
23. Ramphal R, Lhermitte M, Filliat M, Roussel P. The binding of anti-pseudomonal antibiotics to macro-molecules from cystic fibrosis sputum. J Antimicrob Chemother 1988;22:483
24. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
25. Amadori A, Antonelli A, Balteri I, et al. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-13
26. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914
27. Ambrose P, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: its not just for mice anymore. Clin Infect Dis 2007;44:79-86
28. Craig WA. Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12
29. Dalhoff A, Ullmann U. Correlation between pharmacoliketics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990;9:479-87
30. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/ pharmacodynamic target. Antimicrob Agents Chemother 2012;56:2795-805
31. King P, Lomovskayas O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010;54:143-8
32. Sabet M, Miller CE, Nolan TG, et al. Efficacy of aerosol MP-376, o levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:3923-8
33. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53:3847-54
34. Hooper DC, Wolfson JS. Mechanisms of quinolone action and bacterial killing. In: Hooper DC, Wolfson JS, editors. Quinolone antibacterial agents. American Society for Microbiology; Washington DC: 1993. p. 53-75
35. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:3648-63
36. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003;3:359-71
37. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-71
38. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP- 376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-16
39. Bender SW, Posselt HG, Wonne R. Oral ciprofloxacin for Pseudomonas aeruginosa bronchopneumonnia in CF [abstract No. 4.25]. Proceedings of the 9th International Cystic Fibrosis Congress; Brighton, UK; 1984
40. Bilton D, Bruinenberg P, Otulana B, et al. Inhaled liposomal ciorofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Am J Respir Crit Care Med 2009;179:A3214
41. Anonymos. Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis. Available from: Clinical Trials.gov Identifier: NCT00645788 [Last update 30 May 2012]
42. Scully BE, Nakatomi M, Ores C, et al. Ciprofloxacin therapy in cystic fibrosis. Am J Med 1987;82:196-201
43. ORiordan TG, Faris M. Inhaled antimicrobial therapy. Respir Care N Am 1999;5:617-31
44. Berdy J, Aszalos A, Bostian M. CRC handbook of antibiotic compounds. Volume 1 Carbohydrate Antibiotics CRC Press; Boca Raton, FL: 1980
45. Sous H, Loschner H, Lagler F, Muckter H. Experimentelle Untersuchungen uber das Antibiotikum Colistin. Arzneimittelforsch 1961;11:395-400
46. Anonymos. Aztreonam (azactam, Cayston) Selleckchem Catalog No.S1505. Available from: Selleckchen.com/ products/Aztreonam(Azactam).html
47. Bergstrom CAS, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res 2002;19:182-8
48. Olivera ME, Manzo RH, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci 2010; Published online in Wiley InterScience. Available from: www. interscience.wiley.com) DOI 10.1002/ jps.22259
49. Yu X, Zipp GL, Davidson GWR. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm Res 1994;11:522-7
50. Bayer Germany: Ciproxin broad spectrum antibiotic, product monograph, E 22-897/849631
51. Surber MW, Bostian KA, Dudley MN, et al. Aerosolized fluoroquinolones and uses thereof. US8357696B2; 2013
52. Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP.376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55:2636-40
53. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and propabilistic approaches in deriving breakpoints. Infection 2009;37:296-305
54. Lee CKK, Boyle MP, Diener-West M, et al. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 2007;131:796-802
55. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10:258-64
56. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006;31:846-58
57. Sawicki GS, Rasouliyan LR, McMullen AH, et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmol 2011;46:36-44
58. Dalhoff A. A review of quinolone tissue pharmacokinetics. In: Fernadez PB, editor. Quinolones. Proceedings of an international telesymposium. JR Prous Science Publishers; Barcelona, Spain: 1989. p. 277-312
59. Bender SW, Dalhoff A, Shah PM, et al. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 1986;14:17-21
60. LeBel M, Bergeron MG, Vallee F, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimcrob Agents Chemother 1986;30:260-6
61. Goldfarb J, Wormser GP, Inchiosa MA, et al. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol 1986;26:222-36
62. Fabre D, Bressolle F, Gomeni R, et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991;35:2521-5
63. Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013;33(6):419-27
64. Atsushi F, Toshimichi M, Ryota T, et al. Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint. Jpn J Antibiot 1999;52:661-6
65. Gotfried MH, Danzinger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114-22
66. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004;125:965-73
67. Andrews JM, Honeybourne D, Jwevons G, et al. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997;40:573-7
68. Lee CKK, Boyle MP, Diener-West M, et al. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 2007;131:796-802
69. Von Baum H, Bottcher S, Hoffmann H, Sonntag HG. Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. J Antimicrob Chemother 2001;47:729-30